Kajalakshmy M (2022) “Phase Ii Trial Of Bevacizumab, Irinotecan, And Cetuximab In Recurrent Glioblastoma Multiforme: Efficacy, Safety And Clinical Outcomes”, Journal for ReAttach Therapy and Developmental Diversities, 5(2), pp. 788–792. doi: 10.53555/jrtdd.v5i2.3854.